Neil Catton
The Next Evolution Review

Every two months, one question.

Given the room a single essay never has. Free to read, sourced throughout, and nothing in it is a reprint.

The Next
Evolution Review
Issue One · October–November 2026
The distance between proven and permitted
Issue One · October–November 2026

The distance between proven and permitted

When something that works does not reach the people it was built for, how many people had to say yes, and who is answerable for the time they took?

33 pages. A cover story and ten articles across six sections.

The ledger of cases

Twelve cases. Who holds the authority to say yes?

Ten graded against the issue’s own argument, including the ones it fails to explain. Two shown for comparison. Open any case.

2 Explains

OPM-MEG brain scanner
Where it stood, September 2026
Research use since 2021; not used clinically; approval hoped for 2027
What holds it
Device approval, then evidence assessment, commissioning, trust budget
Who carries the cost
Patients who could have been scanned clinically
Confidence
High
In the issue
Cover story
Sources
Wellcome, 7 Jul 2026; UCL News, Oct 2021
Self-healing concrete
Where it stood, September 2026
Full-scale tests from 2011; commercially available; rarely specified
What holds it
Tenders scored on build price
Who carries the cost
Whoever maintains the asset later
Confidence
Low
In the issue
Section 2
Sources
Ingenia, Mar 2011; NWO, Nov 2021; Cabinet Office Construction Playbook v1.1, Sep 2022

2 Partly explains

AI reading of brain MRI (Prima)
Where it stood, September 2026
Validated on 30,000+ studies, published Feb 2026; not in routine care
What holds it
Four approvals ahead of it
Who carries the cost
Patients far from early adopters
Confidence
Low
In the issue
Section 1
Sources
Michigan Medicine, Feb 2026; NHS England, Jul 2025
AI-discovered lung drug (rentosertib)
Where it stood, September 2026
Target to candidate ~18 months; phase III from Jul 2026
What holds it
Trial and approval, deliberately slow
Who carries the cost
People with a named disease
Confidence
Moderate
In the issue
Section 1
Sources
Ren et al., Nature Biotechnology, Mar 2024; Insilico, Jun 2025 and 7 Jul 2026

3 Runs the other way

Public consultation
Where it stood, September 2026
Routine
What holds it
A stage no answer moves
Who carries the cost
People with direct experience
Confidence
Low
In the issue
Section 3
Sources
Author’s argument
Post-quantum cryptography migration
Where it stood, September 2026
NIST standards Aug 2024; NCSC milestones 2028/2031/2035
What holds it
An internal decision, deferred
Who carries the cost
Owners of long-lived records
Confidence
Moderate
In the issue
Section 4
Sources
NIST, Aug 2024; NCSC, 20 Mar 2025
Data profiles
Where it stood, September 2026
Widespread; rectification limited to inaccuracy
What holds it
Nobody’s agreement needed
Who carries the cost
The person described
Confidence
Moderate
In the issue
Section 5
Sources
ICO, Right to rectification guidance

3 Does not explain

Small modular reactors
Where it stood, September 2026
First land-based commercial unit (Linglong One) planned for May 2025; not confirmed operating at 2 Oct 2026
What holds it
Engineering and unit economics
Who carries the cost
Whoever funds the subsidy
Confidence
Moderate
In the issue
Section 2
Sources
NucNet SMR database, accessed Sep 2026; World Nuclear News, 8 Jan 2026
Precision farming
Where it stood, September 2026
Dealer adoption forecasts persistently above actual, 2000-2025
What holds it
Designed for the wrong farm
Who carries the cost
Farmers it was not built for
Confidence
Moderate
In the issue
Section 2
Sources
Malone, Fiechter et al., Agribusiness, 2026
Cyber protection for the smallest organisations
Where it stood, September 2026
Deployed at scale; distributed by ability to pay
What holds it
Price
Who carries the cost
Sole traders and the self-employed
Confidence
High
In the issue
Section 4
Sources
DSIT Cyber security breaches survey 2025/2026, 30 Apr 2026

2 Compared, not graded

Optical atomic clock, naval trial
Where it stood, September 2026
Trialled at sea aboard the Royal Navy’s uncrewed test submarine XCal; announced Oct 2025
What holds it
One authority; nothing further for a trial
Who carries the cost
Nobody; it moved
In the issue
Cover story
Sources
Infleqtion, Oct 2025
Accessibility standards (kerbs, subtitles)
Where it stood, September 2026
Established; wider benefit documented
What holds it
Permission was imposed
Who carries the cost
Nobody; this one arrived
In the issue
Section 6
Sources
Blackwell, SSIR, Winter 2017; Ofcom, 20 May 2013
Dated calls

Three forecasts. Each scored in the first issue after its date, right or wrong.

  1. Linglong One enters commercial operation

    Likely, about 65%

    By 31 December 2026. Confidence: Low.

  2. An OPM-MEG brain scanner receives UK medical device approval for clinical use

    About even, about 45%

    By 31 December 2027. Confidence: Low.

  3. Rentosertib is approved for idiopathic pulmonary fibrosis by any national medicines regulator

    Unlikely, about 30%

    By 31 December 2028. Confidence: Moderate.

How it is built

What every issue carries

  • Cases where the argument failsEach issue includes cases its own argument does not explain, and grades them in the open. Issue One has three.
  • A source for every factual claimNumbered notes in each article’s fact box point to the primary source. Judgements are labelled as judgements.
  • A corrections pageIt appears in every issue, including when it is empty. Issue One carries a correction to an essay published in September.
  • Dated callsForecasts with a stated likelihood and a date. Each is scored in the first issue after its date passes, right or wrong.
  • A three-line summary on every articleThe case, the claim and what it costs, so the whole issue can be skimmed in a few minutes.
  • The data behind the figuresThe ledger of cases and the calls are published as CSV beside each issue, so the arithmetic can be checked.
Why a periodical

An argument that takes six pieces to build is never visible in any one of them.

The longer version

Between July and September 2026, four essays on The Next Evolution made versions of the same argument. The subjects were different and so were the sectors. The point underneath was the same, and the repetition went unrecognised until the fourth.

That is the cost of publishing several times a week. Each piece stands alone, and a reader who arrives at the fourth has no way of knowing the first three exist.

The Review is the slower form. Each issue takes one question, sets a long cover story against it, and gathers shorter articles that come at the same question from other sectors. Where an argument first appeared in shorter form on the Substack, the fact box at the foot of the article names the original.

Next · Issue Two · December 2026–January 2027

The thing that was working before it was measured

What happens when a measurement is introduced to something that was already working, and the measurement changes the thing it was brought in to observe?

It also carries the first case tracker: every case from Issue One with its status updated, and the calls checked against events.

Follow on Substack

If something is wrong, say so.

Corrections are published in the next issue, with the reader credited unless they ask otherwise, and the original is amended with a dated note.

Send a correction

Quote it, cite it, send it on.

Attribution is the only condition. Published every two months and free. There is no subscriber target, and no brief set by anyone other than the author.

Cite as
Catton, N. (2026). The distance between proven and permitted. The Next Evolution Review, Issue 1, October–November 2026.